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Systemic lupus erythematosus (SLE) is a systemic
autoimmune disease with diverse manifestations.
Although the approval of new therapies includes only
one agent in 50 years, a number of promising new
drugs are in development. Lupus nephritis is a dreaded
complication of SLE as it is associated with significant
morbidity and mortality. Advancing the treatment of
lupus nephritis requires well-designed clinical trials and
this can be challenging in SLE. The major obstacles
involve identifying the correct population of patients to
enroll and ensuring that a clinically appropriate and
patient-centered endpoint is being measured. In this
review, we will first discuss the clinical utility of endpoints
chosen to represent lupus nephritis in global disease
activity scales. Second, we will review completed and
active trials focused on lupus nephritis and discuss the
endpoints chosen. There are many important lessons to
be learned from existing assessment tools and clinical
trials. Reviewing these points will help ensure that future
efforts will yield meaningful disease activity measures
and well-designed clinical trials to advance our
understanding of lupus management.points in past and current clinical trials in LN.Introduction
Kidney involvement in lupus, particularly in high-risk
populations, can lead to end-stage kidney disease (ESKD).
Carefully designed trials to identify strategies to calm
flares of lupus nephritis (LN) and identify drug regimens
to maintain remission are essential. Historically, high-dose
corticosteroids were the mainstay of treatment for LN,
and not until the mid-1980s was cyclophosphamide found* Correspondence: kcorapi@partners.org
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unless otherwise stated.to prolong renal survival [1]. Subsequently, glucocorticoid
therapy and cyclophosphamide became the standard
induction regimen. Research has focused on identifying
regimens that allow shorter treatment courses, lower
glucocorticoid doses, and less toxicity [2]. No therapies
are approved for the treatment of systemic lupus erythe-
matosus (SLE) aside from aspirin, prednisone, hydroxy-
chloroquine, and belimumab. In this review, we will focus
on previous and ongoing trials specifically related to the
treatment of LN.
Critical analysis of completed LN clinical trials will
allow us to design effective and meaningful clinical trials
in the future. A well-designed study requires precise in-
clusion and exclusion criteria, guidelines on standardized
steroid dosing, and carefully chosen endpoints. SLE is a
systemic disease, and although a particular treatment
might benefit kidney involvement, an awareness of the
impact on disease activity in other organs is essential.
Numerous global disease activity indices have been de-
veloped to quantify disease activity. In this review, we
will evaluate the renal response criteria within the most
frequently used disease activity indices and determine
whether they can be translated easily into clinical prac-
tice. We will also evaluate the clinical utility of end-Lupus nephritis disease burden
SLE is a complex and potentially life-threatening auto-
immune disease. Kidney involvement, which affects the
majority of patients, remains the most significant cause of
morbid and mortal complications [3,4]. The incidence of
ESKD and the overall mortality among patients with LN
have not improved in populations studied in London,
Toronto, and the United States [5]. In fact, United States
Renal Data System data analysis of trends in outcomes of
ESKD due to incident LN from 1995 to 2006 revealed that
the incidence of ESKD is increasing [6]. In addition, renal
flares may be an independent predictor of incident andThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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lower socioeconomic status have an even worse prognosis
[8-10]. Advances in identification and characterization of
etiologic and pathogenic mechanisms underlying LN have
not led to more effective treatments for LN, despite
advances in the treatment of important co-morbidities,
including diabetes, hyperlipidemia, and hypertension
[4,11,12]. A sobering fact remains: up to 70% of patients
with LN are resistant to current immunosuppressive
regimens [13]. Filling this gap is paramount for the pre-
vention, treatment, and cure of LN. The current clinical
management of patients with LN remains limited to the
use of non-specific cytotoxic drugs despite the advent of
numerous potential biologic agents [3].
Surveillance of lupus nephritis in clinical
nephrology
Kidney involvement in SLE is heralded by either the
presence of proteinuria (>0.5 g/day), active urinary sedi-
ment (with red blood cell, granular, tubular and/or
mixed casts), or an unexplained rise in serum creatinine.
A kidney biopsy is the gold standard to diagnose LN as
it provides information regarding the pattern and sever-
ity of renal involvement as well as the stage, activity, and
chronicity. These are all important considerations influ-
encing treatment decisions [14]. Immunosuppressant
medication is used to halt kidney injury when prolifera-
tive disease is found at biopsy. The pathologic classifica-
tion of LN has evolved—the most recent International
Society of Nephrology/Renal Pathology Society 2003
classification of LN guidelines was published in 2004—in
an effort to better capture the spectrum of kidney in-
volvement [15].
Nephrologists monitor LN activity by trending the es-
timated glomerular filtration rate (eGFR) and proteinuria
and by conducting an interval examination of the urine
sediment. There are several techniques used to deter-
mine eGFR: the Modification of Diet in Renal Disease,
Cockcroft-Gault, or CKD-epi equations. There is no con-
sensus as to which estimating equation is preferred, and
head-to-head comparisons are inconclusive. Each estimat-
ing equation has advantages and disadvantages in certain
clinical settings. Another option is to measure the GFR by
using a 24-hour urine collection; however, this is burden-
some for the patient and open to technique problems such
as under-collection [15-17].
Just as no consensus exists to the best method of de-
termining GFR, there is more than one approach to
determining the quantity of proteinuria. Some centers
use spot urine samples to calculate the urine protein-to-
creatinine ratio, whereas others opt for a 24-hour or
timed sample to quantify protein excretion. Recent work
suggests that the spot protein-to-creatinine ratio may be
inaccurate in the assessment of the degree of proteinuriain LN as compared with other forms of chronic glom-
erular disease; however, prospective studies are needed
to confirm and validate this finding [16].
Finally, serial urinalyses to detect hematuria and re-
examination of the sediment to look for cellular or mixed
casts also help the treating physician determine whether
active kidney involvement persists. An assessment of
eGFR, proteinuria, and urinary sediment is essential to
the early detection of LN flares and to allow prompt
intervention. A standardized approach to each facet of
LN surveillance is needed to allow comparisons of treat-
ment strategies.
Renal subscales in systemic lupus erythematosus
disease activity scales
Given the systemic nature of SLE, it is important to
monitor overall lupus disease activity when instituting
therapy. A treatment may benefit one organ system at
the expense of worsening symptoms in another. Previous
guidance from the US Food and Drug Administration
(FDA) suggests that clinical trials in SLE be designed
with a primary endpoint of overall disease activity [17].
Table 1 summarizes the renal subscales of some of the
commonly used lupus activity instruments [18]. There
are additional disease activity scales, but not all include
a renal subscale [19,20]. In general, the disease activity
scales include various SLE manifestations and the clin-
ician is asked to ascertain the presence or absence of
each by using the definitions supplied and then to estab-
lish the disease activity score.
Disease activity indices that include surveillance pa-
rameters routinely assessed in clinical practice are more
easily translated into clinical use as the physician already
has the necessary data. eGFR and proteinuria are both
objective and routinely measured by treating physicians.
As discussed earlier, recent evidence suggests that a 24-
hour collection is more reliable than a spot urine sample
to quantify proteinuria in LN, albeit much more difficult
for patients to perform [16]. eGFR can be estimated from
one of many equations, but prospective work is needed to
determine the most accurate and reliable equation in LN.
These two measures of kidney function are routinely per-
formed as part of clinical care and are easy to interpret;
thus, their inclusion as endpoints in renal subscales makes
for a seamless transition from a research setting to the
clinic. We feel strongly that any assessment of LN activity
should include a measure of both proteinuria and glom-
erular filtration.
Although the urine sediment gives important clues to
the presence of ongoing nephritis, slide preparation and
interpretation are operator-dependent. Benign kidney dis-
ease such as mesangial proliferation can be associated
with red blood cell (RBC) casts yet would not require im-
munosuppressant treatment, whereas proliferative disease
Table 1 Renal response criteria in global systemic lupus erythematosus scoring tools
Scale Time period Scoring Renal response criteria Strengths and criticisms [18]
Disease activity
SLEDAI-2K [45] 10 days • The presence of each of the
renal manifestations adds 4
points to patient’s total score.
• Urinary casts (heme-granular
or RBC)
✓ Validated for clinical and
research use
• Hematuria (>5 RBCs/hpf) ○ Does not capture
improving or worsening
• Proteinuria (>0.5 g/24 hours,
new onset or increase of >0.5
g/24 hours)
○ Must wait for labs to
score
• Pyuria (>5 WBCs/hpf,
excluding infection)
BILAG [46] One month • Category A (severe disease) =
≥2 of the following:
• Blood pressure ✓ Incorporates an element of
change
1. Proteinuria, defined as • Accelerated hypertension? ✓ Sensitive to small changes
(a) urinary dipstick increased
by 2 or more levels
• Proteinuria (on either dipstick
or 24-hour collection)
✓ Can identify if disease
improving, stable, or worse
(b) 24 urinary protein rising
from <0.20 to >1 g
○ >1 g/24 hours? ± scoring can be complex
(computer program available)
(c) 24 hour urinary protein
rising from >1 g by 100%
○ UPCR >100 mg/mmol?
(d) newly documented
proteinuria of >1 g
• Nephrotic syndrome? ○ Requires formal training
2. Accelerated hypertension • Creatinine ○ Developed for research
3. Deteriorating kidney function,
defined as
• Creatinine clearance/GFR ○ Up to 50 minutes to
complete
(a) plasma creatinine >130
μmol/L and having risen to
>130%
• Active urinary sediment (>5
WBCs/hfp, >5 RBCs/hpf, or
RBC casts)
○ Must wait for labs to
score
(b) creatinine clearance fallen
to <67% of previous value
• Histologic evidence of
nephritis in the previous 3
months? (excludes sclerosis)
(c) creatinine clearance <50
mL/min, and last time was
>50 mL/min or was not
measured
4. Active urinary sediment
5. Histological evidence of active
nephritis
• Category B (moderate disease)
= one of the following:
1. Any one of the category A
criteria above
2. Proteinuria
(a) urinary dipstick which has
risen by 1+ or >2+
(b) 24-hour urinary protein
rising from >1 g by >50%
but <100%
3. Plasma creatinine >130 μmol/L
and having risen 115%
ECLAM One month • 0.5 points for each renal criteria
present
• Proteinuria ≥500 mg/day ✓ Derived from a large
number of real patients and
standardized data
• 2 extra points added if only
kidney involvement
• Urinary casts (RBCs,
hemoglobin, granular, tubular,
or mixed)
✓ Easy to administer and scor
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Table 1 Renal response criteria in global systemic lupus erythematosus scoring tools (Continued)
• 2 points for evolving
manifestations (if any renal
symptom new or worse since
last evaluation)
• Hematuria (micro- or
macro-scopic)
○ Global score will miss
changes in severity over
time
• Raised serum creatinine or
reduced creatinine clearance
SLAM-R One month • Hypertension (diastolic pressure,
mm Hg)
No specific renal response
criteria but the following
components are renal-related:
✓ Evaluates activity and
severity
- 0: <90 • Hypertension ✓ Computerized version
available
- 1: 90-104 • Raised serum creatinine or
reduced creatinine clearance
○ Lacks immunologic
markers
- 2: 105-114 • Severity of urine sediment
analysis per high-power field
○ Not used in major
ongoing clinical trials
- 3: >115
- Unknown
• Serum creatinine or creatinine
clearance (% normal)
- 0: 0.5-1.0 or 80%-100%
- 1: 1.4-2.0 or 60%-79%
- 2: 2.1-4.0 or 30%-59%
- 3: >4.0 or <30%
- Not recorded
• Urine sediment
- 0: normal
- 1: 6-10 RBCs or WBCs OR 0-3
granular or non-RBC casts
OR trace-1+ protein (<500
mg/L 24-hour urine protein)
- 2: 11-25 RBCs or WBCs OR
>3 granular or non-RBC casts
OR 2-3+ protein (>500 mg
to 3.5 g/L 24-hour urine
protein)
- 3: >25 RBCs or WBCs OR any
RBC casts OR 4+ protein
(>3.5 g/L 24-hour urine
protein)
Disease damage
SLICC/ACR Damage
Index [47]
Cumulative
damage index
1 point for satisfying GFR or
proteinuria
• Estimated or measured GFR
<50%
✓ Ability to assess
accumulated damage
3 points if ESKD • Proteinuria ≥3.5 g/24 hours ✓ Prognostic tool
• ESKD ○ Recommended for clinical
trials to describe
population
○ Accuracy depends on
information available
BILAG, British Isles Lupus Assessment Group Index; ECLAM, European Consensus Lupus Activity Measurement; ESKD, end-stage kidney disease; GFR, glomerular
filtration rate; hpf, high-power field; RBC, red blood cell; SLAM-R, Systemic Lupus Activity measure-revised; SLEDAI-2 K, systemic lupus erythematosus Disease
activity index- 2K; SLICC/ACR, Systemic Lupus International Collaborating Clinics/American College of Rheumatology; UPCR, urinary protein-to-creatinine ratio;
WBC, white blood cell.
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ation of the urine sediment alone is insufficient to deter-
mine whether kidney disease is present. A better approach
is demonstrated in the British Isles Lupus AssessmentGroup (BILAG), European Consensus Lupus Activity
Measure, and Systemic Lupus Activity Measure-Revised
renal subscales, which consider the urine sediment in con-
junction with eGFR and proteinuria. As pointed out by
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decisions are placed solely on the urine sediment, repro-
ducibility needs to be demonstrated [21].
The optimal renal subscale is one that is sensitive to
change, whether improvement or deterioration. Both the
magnitude and the presence of change are notable. This
is best captured with serial measurement; therefore,
development of a scale that is easy to administer and
score is preferred. The requirement for formal training
or complicated scoring will impair utility in clinical use.
Renal endpoints in clinical trials of lupus
nephritis: past and present
Completed trials
Glucocorticoids and intermittent intravenous cyclophos-
phamide (IVC) have long been considered the standard
induction agents to treat LN. Steinberg and Decker [22]
reported the success of cyclophosphamide when com-
pared with azathioprine (AZA) or placebo for inducing
remission over the course of a 10-week period in a ran-
domized trial of 38 patients during the mid-1970s. Pa-
tients were evaluated with respect to change in creatinine
clearance, proteinuria, and urine sediment [22]. Amongst
the treatment regimens studied by Austin and colleagues
[1], the authors reported reduced rates of ESKD in a sam-
ple of mostly Caucasian patients who received IVC and
glucocorticoids when compared to glucocorticoid mono-
therapy. LN has remained a research focus in an effort to
identify more effective and less toxic treatment strategies.
Table 2 includes a summary of important randomized
controlled trials for the treatment of LN from the last
15 years. Although these studies have influenced the
care of patients, none has led to FDA approval for an
agent in the treatment of LN. Studies have varied in in-
clusion of patients by race and ethnicity, geographic re-
gion, size, duration of follow-up, and chosen primary
and secondary endpoints.
Studies can be divided into two types: studies of induc-
tion or maintenance of remission. An induction trial com-
pares two treatments with respect to efficacy in achieving
disease remission, whereas maintenance studies compare
therapies with respect to limiting the frequency of flares
[23]. Common endpoints in an induction trial are mea-
sures of disease activity. As demonstrated in Table 2, there
is no standardized definition of ‘complete remission’. The
definitions for remission of proteinuria vary from less than
0.3 g/day [24] to less than 3 g/day [25] to an improvement
of more than 50% [25]. In studies that have included a
measurement of eGFR, definitions of remission differ
from comparisons made to the baseline value [24-26] ver-
sus comparisons made to normal values [27,28]. Trials of
maintenance therapy focus on ‘treatment failure’ as the
primary endpoint. These studies tend to be of longer dur-
ation, which affords them the opportunity to invoke hardendpoints such as patient survival, the need for renal re-
placement therapy, the occurrence of flare, or progressive
kidney disease [29,30].
The trial that assessed efficacy and safety of adding
abatacept to mycophenolate mofetil (MMF) highlights
the need to define endpoints carefully [26]. The definition
of ‘complete response’ chosen by those investigators was
likely too restrictive as it included a composite measure
that required maintenance of eGFR, minimal proteinuria,
and inactive urinary sediment over the 52-week treat-
ment period. This may be one reason why the response
rate among all participants was much lower than ex-
pected [31,32].
It is unethical to deny study participants effective
treatment, and therefore investigators must decide on
a steroid dosing strategy in the trial design. As the
examples in Table 2 illustrate, defining the dose and
type of glucocorticoid to be used for induction is im-
portant but not standardized across trials. In addition,
clinical trials must provide instructions for a taper
and specify how to treat a flare to avoid confounding
due to different cumulative steroid exposure between
groups. Clear guidance on the use of medications, espe-
cially non-steroidal anti-inflammatory drugs (NSAIDs),
angiotensin-converting enzyme inhibitors, or angiotensin
receptor blockers, is also an essential component of trial
design for LN.
The studies done to determine efficacy of MMF for re-
mission of LN illustrate the distinction between superior-
ity and non-inferiority trials. The studies by Chan and
colleagues [24] and Ginzler and colleagues [27] were non-
inferiority trials. Based on the success of MMF in these
trials, the Aspreva Lupus Management Study Group trial
was designed as a superiority trial, and numerous sites
around the globe participated [25,31]. Comparable rates of
patients responded to treatment in the two arms; however,
MMF failed to demonstrate superiority, and therefore this
was considered a negative trial.
Ongoing clinical trials
Four major clinical trials to attempt to improve treat-
ment of LN have recently been completed or are under
way (Table 3). These include the following:
1. The ACCESS trial (Abatacept and Cyclophosphamide
Combination: Efficacy and Safety Study), sponsored
by the National Institute of Allergy and Infectious
Diseases through the Immune Tolerance Network,
assesses the efficacy of abatacept (a fusion protein
composed of the Fc region of IgG1 fused to the
extracellular domain of CTLA-4 that prevents
T-cell activation) versus placebo in the treatment of
proliferative LN (class III or IV with/without class V)
with background therapy of Eurolupus IVC (500 mg
Table 2 An overview of landmark randomized controlled trials of lupus nephritis treatments published since 2000
Reference Study design Number of
patients
Follow-up,
months
Intervention Steroids Endpoint Conclusion
Induction
Chan et al. [24]
(2000)
Randomized, single-
center study
42 12 MMF (1 g BID) versus CYC
(2.5 mg/kg)
Prednisolone 0.8 mg/kg
followed by taper,
maintenance dose 10
mg/day
• Complete remission = Upr <0.3
g/day, with normal sediment,
normal albumin, and SCr and CrCl
≤15% above baseline
Rate of remission similar
between groups
• Partial remission = Upr ≥0.3 and
<2.9 g/day, albumin ≥3.0 g/dL, and
stable kidney function
• Treatment failure = Upr ≥3.0 g/day,
or Upr <3.0 with serum albumin
<3.0 g/dL, SCr that has increased
>0.6 mg/dL, or CrCl >15% above
baseline
Houssiau et al. [48]
(2002)
Randomized non-
inferiority, multicenter
90 41 High CYC (monthly
pulses, dose adjusted
based on WBC) versus
low-dose CYC (500 mg
every 2 weeks)
Methylpred three times
followed by prednisolone
taper, maintenance dose
5 to 7.5 mg/day
• Treatment failure = one of the
following:
Similar treatment failure
rates between groups
○ Absence of a primary response
after 6 months
○ Occurrence of glucocorticoid
resistant flare
○ Doubling of serum creatinine
○ Lack of improvement in kidney
function if dysfunction present
at baseline
Ginzler et al. [27]
(2005)
Randomized, open-label,
non-inferiority
140 6 Oral MMF daily (up to 3
g/day) versus monthly
CYC (up to 1.0 g/m2)
Glucocorticoids 1 mg/kg
per day followed by taper
at clinician’s discretion
• Complete remission: return to
within 10% of normal values for
creatinine, proteinuria, and urine
sediment
MMF was superior to CYC
for induction
Appel et al. [25]
(2009)
Randomized controlled,
superiority trial
370 6 MMF (3 g/day) versus IV
CYC (0.5 to 1.0 g/m2)
Glucocorticoids 60 mg
followed by taper
• Response defined as: Overall response rate the
same in MMF and CYC
groups○ Decrease in UPCR to <3 from a
24-hour collection in patients
with baseline UPCR >3
○ Decrease in UPCR of >50% if
sub-nephrotic at baseline
○ Stabilization (±25%) or
improvement in serum
creatinine
Rovin et al. [28]
(2012)
Randomized, placebo-
controlled, multicenter
144 12 Addition of ritxumab
versus placebo to MMF
and steroids
Methylpred 1 g two times
peri-study drug doses
• Complete renal response = normal
SCr (if abnormal at baseline),
inactive sediment, or UPCR <0.5
Response rates similar
among groups
• Partial renal response = SCr ≤115%
of baseline, RBCs/hpf ≤50% above
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Table 2 An overview of landmark randomized controlled trials of lupus nephritis treatments published since 2000 (Continued)
baseline, no RBC casts, and at least
50% decrease in UPCR or to <1.0 (if
baseline was ≤3.0) or to ≤3.0 (if
baseline was >3.0)
• No response = did not meet
criteria for complete or partial
response, terminated study early, or
missing data limited ability to
assess
Furie et al. [26]
(2014)
Randomized, phase II/III
multicenter, double-blind
study
298 12 Standard dose abatacept,
high-dose abatacept, or
placebo
Protocol defined steroid
(and MMF) dosing
• Complete response = eGFR ≥90%
of screening or pre-flare value,
UPCR <0.26, inactive urinary
sediment
Time to achievement of
complete response was
similar in all arms.
ACCESS trial group,
2014 [33]
Randomized double
blind, double-blind,
placebo-controlled
134 6 and 12
weeks
Euro-Lupus CYC with
abatacept versus placebo
Methyl pred x3 followed
by taper
Proportion of subjects achieving
complete response at 24 weeks
defined as:
No difference with
abatacept
• Kidney function: stable or improved
eGFR
• Proteinuria: UPCR <0.5
• Urine sediment: not included
• Corticosteroid dose: tapered to ≤10
mg daily
Maintenance
Contreras et al.
[29] (2004)
Single-center, randomized
open-label trial
60 72 IV CYC (0.5 to 1.0 g/m2
every 3 months) or AZA 1
to 3 mg/kg per day or
MMF (500 to 3,000 mg/
day)
Glucocorticoids up to 0.5
mg/kg per day
• Patient survival Patient survival was
significantly better in AZA
compared with CYC, and
renal survival was similar
in all groups.
• Renal survival, defined as sustained
increase in SCr to at least two times
the lowest level achieved during
induction, need for RRT or
transplant
Houssiau et al.
[49] (2010)
Randomized trial 105 48 AZA (target 2 mg/kg per
day) or MMF (target 2 g/
day)
Methylpred three times
followed by taper
• Time to renal flare = nephrotic
syndrome, ≥33% increase in serum
creatinine within 1 month,
threefold increase in 24-hour
proteinuria with hematuria, ≥ 33%
reduction in C3 within 3 months
Fewer flares with AZA but
failed to show superiority
Dooley et al.
[30] (2011)
Randomized double-
blind, double-dummy,
multicenter
227 36 MMF (1 g BID) versus
AZA (2 mg/kg daily)
Glucocorticoids 10 mg/
day
• Time to treatment failure = time
until the first event (death, ESKD,
doubling of SCr, renal flare, or need
for rescue therapy)
MMF superior to AZA
ACCESS, Abatacept and Cyclophosphamide Combination: Efficacy and Safety Study; AZA, azathioprine; BID, twice a day; CrCl, creatinine clearance; CYC, cystatin C; eGFR, estimated glomerular filtration rate; ESKD,
end-stage kidney disease; hpf, high-power field; IV, intravenous; Methylpred, methylprednisolone; MMF, mycophenolate mofetil; RBC, red blood cell; RRT, renal replacement therapy; SCr, serum creatinine; UPCR, urinary
protein-to-creatinine ratio; Upr, urinary protein excretion; WBC, white blood cell.
C
orapiet
al.A
rthritis
Research
&
Therapy
 (2015) 17:110 
Page
7
of
13
Table 3 An overview of major randomized controlled trials of lupus nephritis treatments currently in progress and their response criteria
ClinicalTrials.
gov identifier
Sponsor Study
name
Study design Lupus
nephritis
class
Intervention Background
therapy
Primary outcome Patient
enrollment
goal,
number
Sites,
number
International
or US only
Estimated
completion
date
NCT01714817 Bristol-Myers
Squibb
ALLURE Phase 3,
randomized,
double-blind,
placebo-
controlled
III or IV Abatacept versus
placebo
Corticosteroids +
MMF
Proportion of subjects
achieving complete
renal response at
52 weeks defined as:
400 98 International July 2017
1. Kidney function:
eGFR normal or no
less than 85%
baseline
2. Proteinuria: UPC
ratio <0.5
3. Urine sediment: no
cellular casts
4. Corticosteroid dose:
<11 mg daily for at
least 28 days
NCT01639339 Human Genome
Sciences Inc., a
GSK Company
BLISS-LN Phase 3,
randomized,
double-blind,
placebo-
controlled
III or IV and
coexisting V
if present
Belimumab versus
placebo
Corticosteroids +
CYC for induction
therapy
Number of
participants with
complete renal
response at
104 weeks defined as:
464 102 International February
2017
1. Kidney function:
eGFR no more than
10% below pre-flare
value or normal
-AZA for
maintenance OR
High-dose
steroids + MMF for
induction therapy
-MMF for
maintenance
2. Proteinuria: UPC
ratio <0.5
3. Urine sediment:
inactive (<5 RBCs/
WBCs, no casts)
4. No rescue therapy
Biogen IDEC ATLAS Randomized,
double-blind,
placebo-
controlled
III or IV and
coexisting V
if present
BIIB023 (anti-
TWEAK) at high or
low dose versus
placebo
Corticosteroids +
MMF
Proportion of subjects
who achieve renal
response (complete
or partial) at 52 weeks
300 123 International September
2016
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Table 3 An overview of major randomized controlled trials of lupus nephritis treatments currently in progress and their response criteria (Continued)
NCT02141672 Aurinia AURA-LV Randomized,
double-blind,
placebo-
controlled
III, IV and/
or V
Voclosporin at
high or low dose
versus placebo
Corticosteroids +
MMF
Number of subjects
who achieve
complete remission at
24 weeks defined as:
222 56 Inter-national December
2016
1. No confirmed
decrease from
baseline in eGFR of
≥20%
2. Proteinuria: UPC
ratio <0.5
ALLURE, Advancing Leading-Edge Lupus Research; ATLAS, Adjuvant Tamoxifen: AURA-LV, Aurinia Urinary Protein Reduction Active – Lupus with Voclosporin; Longer Against Shorter; AZA, azathioprine; BLISS-LN,
Belimumab International Lupus Nephritis Study; CYC, cystatin C; eGFR, estimated glomerular filtration rate; MMF, mycophenolate mofetil; RBC, red blood cell; TWEAK, tumor necrosis factor-related weak inducer of
apoptosis; UPC, urine protein-to-creatinine; WBC, white blood cell.
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maintenance with AZA [33,34].
2. The ALLURE (Advancing Leading-Edge Lupus
Research) trial also assesses the efficacy of abatacept
with background therapy of MMF.
3. The BLISS-LN (Belimumab International Lupus
Nephritis Study) trial assesses the efficacy of
belimumab—a human monoclonal antibody
that inhibits the B-cell survival factor called
B-cell activating factor (BAFF; also known as
B-lymphocyte stimulator or BLyS) to prevent B-cell
survival—with background therapy of Eurolupus
IVC or MMF per investigator choice followed by
MMF maintenance.
4. The ATLAS (Adjuvant Tamoxifen: Longer Against
Shorter) trial assesses the efficacy of BIIB023—a
humanized monoclonal antibody that inhibits tumor
necrosis factor-related weak inducer of apoptosis
(TWEAK) to reduce tissue inflammation—with
background therapy of MMF.
All four clinical trials use glucocorticoids as standard-
of-care therapy. The ACCESS trial and BLISS-LN trial
allow IVC remission induction therapy as another op-
tion. The ACCESS trial has completed 1-year follow-up
data collection on the 134 participants, and the interim
data have been published as abstracts [35]. The remaining
three clinical trials are led by pharmaceutical companies
and are attempting to recruit hundreds of patients from
many national and international sites.
Each trial is designed with a primary, composite end-
point of complete renal response; however the criterion
used in the endpoint definition varies across studies.
Aside from the ACCESS trial, each study includes micro-
scopic review of the urine sediment, namely looking for
RBC casts, as a part of the composite endpoint. This may
be questioned upon trial completion given the variability
in an investigator’s ability to reliably and uniformly assess
the sediment at each site. While a multi-faceted definition
of complete renal response reflects the approach used in
clinical care, it is likely difficult to achieve in a research
setting, especially in a diverse group of patients recruited
from centers around the world.
Surrogate endpoints in chronic kidney disease
trials
Clinical trials should be centered on improving outcomes
that matter to patients. In the case of LN, many would
agree that the prevention of the need for renal replacement
therapy is the clinical endpoint of most concern. However,
clinical trials often cannot afford to have as many years of
follow-up as the early study by Austin and colleagues. As a
result, many clinical trials are designed around surrogate
endpoints. The National Institutes of Health defines asurrogate endpoint as a ‘biomarker intended to substitute
for a clinical endpoint’; that is, a surrogate endpoint is a
marker of a treatment effect that may correlate com-
pletely with a real clinical endpoint, but this relationship
does not always hold true [36]. Surrogate endpoints are
selected on the basis of their ability to predict the effect
of a treatment on the clinical endpoint of interest [37,38].
The FDA allows for initial drug approval based on studies
using surrogate endpoints with the caveat that post-
marketing surveillance be performed to define long-term
effects [39].
The development of novel agents for the treatment of
CKD, from any cause, has been plagued by the need to
identify appropriate surrogate endpoints. In diabetic ne-
phropathy, the initial approvals for angiotensin-converting
enzyme inhibitors and angiotensin receptor blockers relied
on a doubling of serum creatinine, ESKD, or death as
endpoints. Approval of newer agents to treat diabetic
nephropathy, like that of agents to treat LN, has stalled
while appropriate surrogate endpoints are defined [40].
Fortunately, the FDA and the American Society of Neph-
rology recently founded a public and private partnership
of all stakeholders that is called the Kidney Health Initia-
tive, which likely will facilitate development of appropriate
surrogate endpoints in LN and other forms of kidney
disease [41].
Surrogate endpoints commonly used in clinical trials
of CKD include eGFR and proteinuria. Stevens and col-
leagues [37] published a thorough review of surrogate end-
points in trials of kidney disease several years ago, and we
will summarize that review here. By definition, there must
be a decrease in GFR for a patient to develop kidney fail-
ure, making substantial changes in GFR a reasonable inter-
mediate endpoint for ESKD. However, changes in GFR are
sometimes not appreciated in the early stages of kidney
disease, and in the case of slowly progressive kidney dis-
ease, this may not be a useful endpoint if follow-up is not
long enough. eGFR is considered to be a reflection of the
number of functioning nephrons; however, glomerular
hyperfiltration, glomerular hypertension, kidney perfusion,
pregnancy, and medications including but not limited to
NSAIDs all influence GFR and may interfere with inter-
pretation [37].
The majority of patients with LN are women, who
often have lower muscle mass and thus lower serum
creatinine values and may be obese because of steroid
exposure. Many clinical trials focus on patients with
relatively preserved renal function. The current methods
for estimating GFR are less precise with eGFR of more
than 60 mL/min per m2. The search for a method less
affected by weight and muscle mass to more precisely
assess change in eGFR would strengthen this criterion as
an outcome variable. Recent research assessing GFR
employing cystatin C or iohexol dissipation in young
Table 4 Take home points
1. Kidney disease activity rating scales in systemic lupus
erythematosus should include the following:
•A measure of estimated glomerular filtration rate (eGFR)
◦Using consensus-based equation
•A measure of proteinuria
◦Using 24-hour collection
•Analysis of urine sediment only in conjunction with above
2. Guidelines for future trials of lupus nephritis:
•Complete response should be a composite endpoint
of the following:
◦Proteinuria of less than 0.3 g/day
◦eGFR:
▪Stable (if more than 60 mL/min per m2 at
baseline) or
▪Improvement of at least 50% (if less than 60
mL/min per m2 at baseline)
◦Consider repeat biopsy in patients meeting
criteria for response or non-response
◦Reduction or discontinuation of glucocorticoids
•Treatment failure should be a composite of the following:
◦Need for renal replacement therapy or transplant
◦Persistent doubling of serum creatinine
◦eGFR decrease by at least 50%
◦Renal flare requiring treatment
◦Death
•Design should require 12 to 24 months of follow-up.
•Detailed guidance on steroid dosing should be provided.
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tion may prove more helpful [42,43].
The power of a slope-based analysis can be jeopar-
dized if the rate of underlying disease progression is not
uniform over time or stage of disease. The use of a time-
to-event analysis with a composite endpoint made up of
objective endpoints such as the need for dialysis, a desig-
nated reduction in GFR, and an increase in serum cre-
atinine helps circumvent some of these concerns [37].
Proteinuria has also been used as a surrogate endpoint
because it correlates well with GFR and has been impli-
cated in the pathogenesis of CKD. It is an attractive
choice because, following an intervention, the change in
proteinuria is often earlier and larger than the observed
change in GFR. It might be useful therefore in slowly
progressive or early stages of disease. The presence of or
a change in proteinuria, unlike GFR, is not a mandatory
intermediary in the development of kidney failure. As a
result, proteinuria must be validated as a surrogate end-
point and this has yet to be done [37]. Complicating the
search for surrogate markers are recent reports of pa-
tients with LN undergoing protocol repeat renal biopsy
at defined time points regardless of clinical status. These
have shown a significant discordance between complete
or partial remissions defined by the measures above and
histologic remissions. These results raise concern that
repeat renal biopsy protocols may be required to define
surrogate outcome measures for LN [44].
Moving forward
Just as lupus is a multisystem disease, the design and exe-
cution of trials should be multidisciplinary. Input from ne-
phrologists and rheumatologists who routinely care for
patients with LN will help ensure that appropriate inclu-
sion/exclusion criteria are chosen and that the selected
primary and secondary endpoints are clinically meaning-
ful. Although treatment options in LN have stalled, much
can be learned from the trials that have been completed.
Time and again, we have seen success in early studies
that was not replicated in multicenter, randomized,
placebo-controlled trials. Investigators are charged with
demonstrating that the addition of a study drug is more
effective than usual care with steroids and current cyto-
toxic agents with respect to controlling disease, avoiding
relapses, or lessening drug toxicity [23]. Given the many
side effects associated with steroids, trials typically use
and should continue to use a step-down design. This in-
volves starting two agents simultaneously (for example,
MMF and prednisone) and then reducing the dose of
one agent (in this case, steroids) [23]. A treatment with
similar efficacy that allows for steroid reduction would
be a favorable option to clinicians and patients. Reduc-
tion in steroid dose is also an important endpoint that is
not often used in clinical trials of LN.The endpoints that we, as treating nephrologists and
rheumatologists, favor for future clinical trials are com-
posite endpoints that include assessment of GFR and
proteinuria. For complete response, we favor proteinuria
of less than 0.3 g, regardless of the starting point. The
measure of GFR should account for change rather than
a static arbitrary value. In patients with or without clinical
response, a repeat kidney biopsy would provide definitive
evidence of histologic response, including remission, and
help validate the chosen surrogate endpoints. Just as a re-
duction in GFR is an inherent feature of kidney injury,
persistent histologic evidence of proliferative nephritis sig-
nifies ongoing active kidney injury. GFR and proteinuria
do not necessarily change as quickly as one another nor as
quickly as the histology in a glomerulus. Therefore, to en-
sure that follow-up is long enough to permit change, clin-
ical trials should include at least 12 (and, ideally, 24)
months of follow-up. Table 4 includes a summary of our
suggested endpoints in LN trials.
All study participants must be offered effective treat-
ment such as steroids, anti-malarial agents, angiotensin-
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blockers, and HMG-CoA reductase inhibitors. Patients
entering a trial should receive the same regimen of glu-
cocorticoids with a standard tapering schedule [23]. For
example, the abatacept trial did not restrict steroid dos-
ing, and the analysis observed a trend of higher mean
prednisone dose among the placebo group, confounding
interpretation of the data [26].
Lupus has diverse manifestations, and this is likely due
to numerous subtypes of disease. Studying new agents in a
more homogeneous patient sample may increase the yield
of positive findings. The research into rituximab illustrates
this point. The earlier uncontrolled trials were of patients
who failed initial therapy with cyclophosphamide or
MMF, whereas the LUNAR (Lupus Nephritis Assessment
with Rituximab) project enrolled patients receiving initial
treatment [31]. It must also be realized, though, that using
more inclusion and exclusion criteria must be weighed
against the difficulties of patient recruitment.
Conclusions
The diverse manifestations of SLE pose challenges in the
design of clinical trials. To capture disease activity, various
disease activity indices have been developed. Thesevary in
length and complexity, and many have renal subscales.
The renal subscales, particularly in the SLEDAI-2 K (Sys-
temic Lupus Erythematosus Disease Activity Index 2000)
and BILAG tools, measure clinically meaningful parame-
ters of kidney involvement, namely eGFR and proteinuria
(Table 4). It is important that the best method to define
eGFR and proteinuria in LN be identified and then
adopted into clinical care and trial design. To advance
the knowledge of how to treat LN, well-designed clinical
trials informed by prior randomized controlled trials are
needed. Clinical trials should have thoughtful inclusion
and exclusion criteria, pre-specified dosing parameters
for glucocorticoids and other medications, and well-
designed endpoints.Note: This article is part of the series ‘Measuring meaningful
change in lupus clinical trials’, edited by Matthew Liang and
Chan-Bum Choi. Other articles in this series can be found at
http://arthritis-research.com/series/trialsAbbreviations
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